



Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing researchers' discoveries to the public, but can present the potential for conflicts of interest with respect to their research activities.

Cleveland Clinic has policies and procedures in place to identify potential conflicts of interest to safeguard the objectivity of research taking place at Cleveland Clinic. Cleveland Clinic requires any person who is responsible for the design, conduct or reporting of Public Health Service (PHS)-funded research at Cleveland Clinic to disclose their outside financial interests every year as well as whenever there is a change to their interests. Cleveland Clinic's Innovation Management and Conflict of Interest Program reviews all disclosures in relation to the researchers' proposed and ongoing research projects to determine whether the financial interests are related to the research activities and whether they create a PHS-Reportable Financial Conflict of Interest.

Cleveland Clinic, its physicians and scientists advocate transparency with respect to relationships with industry. Accordingly, Cleveland Clinic provides the public certain information regarding PHS-Reportable Financial Conflicts of Interest via this webpage.

As PHS grants come up for funding or renewal, they will be evaluated for potential PHS-Reportable Financial Conflicts of Interest. As these are identified, they will be listed on this page. Cleveland Clinic will maintain this listing by updating it at least annually and whenever a new PHS-Reportable Financial Conflicts of Interest is identified.

As of May 8, 2017, Cleveland Clinic has identified the following Public Health Service-Reportable Financial Conflicts of Interest under *Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors*, 76 Fed. Reg. 53,256 (Aug. 25, 2011) (codified at 42 C.F.R. Part 50 Subpart F and 42 C.F.R. Part 94).

**Maciej Zborowski, Ph.D.**

**Principal Investigator**

Dr. Zborowski is entitled to a portion of any royalty payments Cleveland Clinic receives from IKOtech, LLC, Precelleon, Inc. and Ward Engineering for technology he developed. In the previous 12-months, Dr. Zborowski received between \$0 - \$4,999.

**Imre Noth, M.D.**

**The University of Chicago Subaward Principal Investigator**

Dr. Noth disclosed receiving \$10,000 - \$19,999 in payment for consulting services from Immuneworks, Inc. in the previous 12-months. Dr. Noth also has

Intellectual Property rights for technology licensed to Celgene Corporation from the University of Pittsburgh. In the previous 12-months, Dr. Noth received between \$0 - \$4,999 from Celgene.

**Stanley Hazen, M.D., Ph.D.**

**Principal Investigator**

Dr. Hazen disclosed receiving \$200,000 - \$299,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Cleveland HeartLab, Inc. as well as holding equity in the company with an estimated value between \$10,000 - \$19,999.

**Stanley Hazen, M.D., Ph.D.**

**Principal Investigator**

Dr. Hazen disclosed receiving \$20,000 - \$39,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Liposcience, Inc. Dr. Hazen disclosed receiving \$40,000 - \$59,999 in fees for services from the company in the previous 12-months.

**Stanley Hazen, M.D., Ph.D.**

**Principal Investigator**

Dr. Hazen disclosed receiving \$5,000 - \$9,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Esperion Therapeutics, Inc. Dr. Hazen disclosed receiving \$20,000 - \$39,999 in fees for services from the company in the previous 12-months.

**Zeneng Wang, Ph.D.**

**Project Scientist**

Dr. Wang discloses receiving \$0 - \$4,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Liposcience, Inc.

**Renliang Zhang, M.D., Ph.D.**

**Core Director**

Dr. Zhang disclosed receiving \$40,000 - \$59,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Cleveland HeartLab, Inc.

**Courtenay Moore, M.D.**

**Co-Investigator**

Dr. Moore disclosed receiving \$0 - \$4,999 from Allergan, Inc. in the previous 12-months as consideration for serving on a scientific advisory board and for serving as a speaker, trainer or educator.

**Jaroslaw Maciejewski, M.D., Ph.D., FACP**

**Co-Investigator**

Dr. Maciejewski disclosed receiving \$10,000 - \$19,999 from Eisai Co., Ltd. in the previous 12-months as consideration for serving as a speaker, trainer or educator.

**Jonathan Smith, Ph.D.**

**Project Director**

Dr. Smith disclosed receiving \$20,000 - \$39,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Esperion Therapeutics, Inc. Dr. Smith disclosed receiving \$20,000 - \$39,999 in fees for services from the company in the previous 12-months.

**Anthony Calabro, Jr., Ph.D.**

**Co-Investigator**

Dr. Calabro is entitled to a portion of any royalty payments Cleveland Clinic receives from Lifecore Biomedical, LLC for technology he developed. In the previous 12-months, Dr. Calabro received between \$0 - \$4,999.

**William J. Dupps, Jr., M.D., Ph.D.**

**Principal Investigator**

Dr. Dupps disclosed receiving \$10,000 - \$19,999 in commercialization revenues from Avedro, Inc. in the previous 12-months for technology he developed. Cleveland Clinic and Avedro entered into an exclusive option agreement for this technology.

**Andrew Rollins, Ph.D.**

**Case Western Reserve University Co-Investigator**

Dr. Rollins disclosed receiving \$0 - \$4,999 in commercialization revenues from OptoQuest, Inc. in the previous 12-months for technology he developed. Cleveland Clinic and Avedro entered into an exclusive option agreement for this technology.

**Philip Schauer, M.D.**

**Co-Principal Investigator**

Dr. Schauer disclosed receiving \$10,000 - \$19,999 in payments for services from Ethicon Endo-Surgery, Inc. in the previous 12-months.

**Sandip Vasavada, M.D.**

**Co-Investigator**

Dr. Vasavada disclosed receiving \$10,000 - \$19,999 from Medtronic, Inc. in the previous 12-months as consideration for serving as a speaker, trainer or educator.

**Jaroslaw Maciejewski, M.D., Ph.D., FACP**

**Co-Investigator**

Dr. Maciejewski disclosed receiving \$10,000 - \$19,999 from Celgene Corporation in the previous 12-months as consideration for serving as a speaker, trainer or educator.

**Miriam Cremer, M.D., M.P.H.**

**Principal Investigator**

Dr. Cremer disclosed receiving \$200,000 - \$250,000 in the previous 12-months from Basic Health International for serving as founder and global head of clinical and medical services.

**Vinod Labhasetwar, Ph.D.**

**Principal Investigator**

Dr. Labhasetwar disclosed holding equity in ProTransit Nanotherapy, LLC. The financial interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**A. Marc Gillinov, M.D.**

**Principal Investigator**

Dr. Gillinov disclosed receiving \$20,000 - \$39,999 from Edwards Lifesciences, LLC in the previous 12-months as consideration for serving as a consultant and speaker, trainer or educator.

**Jose Navia, M.D.**

**Co-Investigator**

Dr. Navia disclosed receiving \$5,000 - \$9,999 from Edwards Lifesciences, LLC in the previous 12-months for serving as a speaker, trainer or educator.

**Douglas Johnston, M.D.**

**Co-Investigator**

Dr. Johnston disclosed receiving \$5,000 - \$9,999 from Edwards Lifesciences, LLC in the previous 12-months for serving as a speaker, trainer or educator.

**Jan Jensen, Ph.D.**

**Principal Investigator**

Dr. Jensen disclosed holding equity in a non-publicly traded entity. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**Andre Machado, M.D., Ph.D.**

**Principal Investigator**

Dr. Machado disclosed holding equity in a non-publicly traded entity, Enspire DBS Therapy, Inc. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**Yogen Saunthararajah, M.D.**

**Investigational New Drug (IND) Holder**

Dr. Saunthararajah disclosed receiving \$0 - \$4,999 in commercialization revenues from Epidestiny, LLC and DeNovoTherapies, LLC for technology he developed. University of Illinois Chicago entered into a license agreement for this technology.

**Edward Plow, Ph.D.**

**Principal Investigator**

Dr. Plow disclosed holding equity in a non-publicly traded entity, Sujana Biotech, LLC. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.